Let The Blame Game Begin: Former Ranbaxy Promoter Spars With Daiichi Sankyo
This article was originally published in PharmAsia News
Executive Summary
PharmAsia News speaks to former CEO Malvinder Singh and U.S. whistleblower Dinesh Thakur, as the stakes continue to rise in the ongoing saga of India’s Ranbaxy.
You may also be interested in...
Ranbaxy Sees Light At The End Of DoJ Investigation Tunnel - CEO Interview
MUMBAI - India's largest drug maker Ranbaxy is confident that the U.S. Department of Justice will soon withdraw its motion filed against the company, Ranbaxy CEO Malvinder Singh said in an interview with PharmAsia News
Japan’s Daiichi Sankyo In “Transformational” Deal to Buy Majority Stake In India’s Ranbaxy Labs
NEW DELHI - Japan's Daiichi Sankyo will buy a majority stake in India's top drug maker in a deal that will vault the combined operations into the top 15 pharmaceutical firms globally and end the founding Singh family's role as largest shareholder of Ranbaxy Laboratories
Cynata Sets Stage For Global Fujifilm Cell Therapy Deal
Cynata has inched closer to a major global partnership after signing a term sheet with Fujifilm for cell therapy technologies that has been described by analysts as a potentially transformative deal.